Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the age of 18 and 70 years, inclusive, at time of enrollment.~* Subject has never received antiviral treatment for hepatitis C virus (HCV) infection.~* Body mass index (BMI) is ≥ 18 to \< 38 kg/m\^2. BMI is calculated as weight measured in kilograms (kg) divided by the square of height measured in meters (m).~* Chronic HCV genotype 1-infection for at least 6 months prior to study enrollment.~* Subject has plasma HCV RNA level \> 10,000 IU/mL at screening~Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to any drug.~* Females who are or plan to become pregnant or breastfeeding or males whose partner is pregnant or planning to become pregnant.~* Recent history of drug or alcohol abuse that could preclude adherence to the protocol.~* Positive test result for hepatitis B surface antigen or anti-human immunodeficiency virus (HIV) antibodies.~* Any current or past clinical evidence of cirrhosis (e.g., ascites, esophageal varices), or a liver biopsy or FibroTest/aspartate aminotransferase to platelet ratio (APRI) or FibroScan® showing cirrhosis or extensive bridging fibrosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV (Type: EXPERIMENTAL): ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
- ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV (Type: EXPERIMENTAL): ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).